SCHEMBL4312085

SCHEMBL4312085

Cc1ccsc1C(=O)Nc1cc(CN(CCO)CCN2CCOCC2)ccc1/C=C/c1n[nH]c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 6/20 0.60
▸ AURKB Q96GD4 6/20 0.60
▸ HTR1A P08908 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ GFER P55789 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CASR P41180 2/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ PLK4 O00444 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4312089 1.00 AURKA (0.60) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL14989337 0.90 AURKA (0.49) AURKAAURKBALDH1A1KDM4ENPC1
SCHEMBL14989354 0.90 AURKB (0.70) AURKAAURKBGFERMAPK14PLK4
SCHEMBL14989352 0.90 AURKB (0.70) AURKAAURKBGFERMAPK14PLK4
SCHEMBL14989031 0.88 AURKB (0.72) AURKAAURKBNPC1RAB9AMAPK14
SCHEMBL14989033 0.88 AURKB (0.72) AURKAAURKBNPC1RAB9AMAPK14
Hydrochloric Acid SCHEMBL4314035 0.88 AURKB (0.71) AURKAAURKBNPC1RAB9AMAPK14
Hydrochloric Acid SCHEMBL4314042 0.88 AURKB (0.71) AURKAAURKBNPC1RAB9AMAPK14
SCHEMBL4317385 0.88 AURKA (0.55) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4317390 0.88 AURKA (0.55) AURKAAURKBHTR1ADRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885HTR1A 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback